Ryvu Therapeutics SA

DelveInsight's 'Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024' covers 50+ companies and 75+ pipeline drugs, including clinical and nonclinical stage products, with therapeutic assessments by product type, stage, route of administration, and molecule type. Key companies and therapies highlighted.